MedTrace Logo

Erythropoietin Gel as an Adjunct to Split-Thickness Apically Positioned Flap in Augmentation of Attached Gingiva

NCT05683782 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-01-13

No results posted yet for this study

Summary

This study will be carried out to evaluate the effect of topical application of erythropoietin gel as an adjunct to split-thickness apically positioned flap regarding Wound Healing and the Effect on post-surgical symptoms \[ Patient Satisfaction\] (1ry objective) and Clinical gain in width of attached gingiva. (2ry objective).

Conditions

  • Erythropoietin
  • Recession

Interventions

DRUG

Split thickness Apically positioned flap with Chitosan based Erythropoietin Gel application

Split thickness Apically positioned flap will be performed to increase width of attached gingiva .1 mL of EPO-loaded with chitosan 5% and β-glycerophosphate disodium salt (GP) 20% gel will be used by the patient two times daily for 14 days.

DRUG

Split thickness Apically positioned flap without Erythropoietin application

Split thickness Apically positioned flap will be performed to increase width of attached gingiva.The patient will use a Chitosan gel without being loaded with erythropoietin two times daily for 14 days

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Ahmed E Amr, Assoc.Prof · Ain Shams University

  • Hala k Abdelgaber, Professor · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2023-07-31
Completion
2023-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05683782 on ClinicalTrials.gov